These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21170920)

  • 1. Discriminant analysis using a multivariate linear mixed model with a normal mixture in the random effects distribution.
    Komárek A; Hansen BE; Kuiper EM; van Buuren HR; Lesaffre E
    Stat Med; 2010 Dec; 29(30):3267-83. PubMed ID: 21170920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of an outcome using trajectories estimated from a linear mixed model.
    Maruyama N; Takahashi F; Takeuchi M
    J Biopharm Stat; 2009 Sep; 19(5):779-90. PubMed ID: 20183443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robustness of a parametric model for informatively censored bivariate longitudinal data under misspecification of its distributional assumptions: A simulation study.
    Pantazis N; Touloumi G
    Stat Med; 2007 Dec; 26(30):5473-85. PubMed ID: 18058854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.
    Chan CW; Gunsar F; Feudjo M; Rigamonti C; Vlachogiannakos J; Carpenter JR; Burroughs AK
    Aliment Pharmacol Ther; 2005 Feb; 21(3):217-26. PubMed ID: 15691295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting renal graft failure using multivariate longitudinal profiles.
    Fieuws S; Verbeke G; Maes B; Vanrenterghem Y
    Biostatistics; 2008 Jul; 9(3):419-31. PubMed ID: 18056686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-term beneficial effects of ursodeoxycholic acid in primary biliary cirrhosis are highly questionable.
    Yan G; Erik C; Gluud C
    Am J Gastroenterol; 2007 Feb; 102(2):464-5. PubMed ID: 17311669
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficient estimation for patient-specific rates of disease progression using nonnormal linear mixed models.
    Zhang P; Song PX; Qu A; Greene T
    Biometrics; 2008 Mar; 64(1):29-38. PubMed ID: 17501938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.
    ter Borg PC; Schalm SW; Hansen BE; van Buuren HR;
    Am J Gastroenterol; 2006 Sep; 101(9):2044-50. PubMed ID: 16848809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mixed mover-stayer model for spatiotemporal two-state processes.
    Nathoo F; Dean CB
    Biometrics; 2007 Sep; 63(3):881-91. PubMed ID: 17825018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
    Hay JE
    Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The timing of liver transplantation in primary biliary cirrhosis.
    Angulo P; Dickson ER
    Baillieres Best Pract Res Clin Gastroenterol; 2000 Aug; 14(4):657-68. PubMed ID: 10976021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodeoxycholic acid in primary biliary cirrhosis.
    Combes B
    Semin Liver Dis; 1997 May; 17(2):125-8. PubMed ID: 9170199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach.
    Faucett CL; Thomas DC
    Stat Med; 1996 Aug; 15(15):1663-85. PubMed ID: 8858789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre.
    Floreani A; Caroli D; Variola A; Rizzotto ER; Antoniazzi S; Chiaramonte M; Cazzagon N; Brombin C; Salmaso L; Baldo V
    Liver Int; 2011 Mar; 31(3):361-8. PubMed ID: 21059170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment.
    Huet PM; Vincent C; Deslaurier J; Coté J; Matsutami S; Boileau R; Huet-van Kerckvoorde J
    Gastroenterology; 2008 Nov; 135(5):1552-60. PubMed ID: 18722374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
    Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Good prognosis in asymptomatic primary biliary cirrhosis].
    Lööf L; Lindgren S
    Lakartidningen; 2010 May 26-Jun 1; 107(21):1396-8. PubMed ID: 20645617
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.